<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04876833</url>
  </required_header>
  <id_info>
    <org_study_id>MR-61-21-012951</org_study_id>
    <nct_id>NCT04876833</nct_id>
  </id_info>
  <brief_title>Characteristics of Intestinal Microbiome in the Progression of Early COPD</brief_title>
  <official_title>Characteristics of Intestinal Microbiome in the Progression of Early Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aiming at explore the characteristics of intestinal microbiome during the early&#xD;
      progression of COPD, the correlation between the changes of intestinal microbiome and the&#xD;
      severity and risk of acute exacerbation of COPD, the correlation between microbial&#xD;
      metabolites SCFA and immune function of COPD. Then reveal the influence of intestinal&#xD;
      microecology on the development of COPD and the possible mechanism of intestinal microecology&#xD;
      in the pathogenesis of COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Invite participants according to inclusion criteria and exclusion criteria and divide&#xD;
           them into 4 groups, including healthy control (HC), high-risk COPD group (HG), early&#xD;
           COPD group (EG), mild and moderate COPD group (MG). Research contents will be explained&#xD;
           detailedly to the participants, and the healthy participants and COPD patients who&#xD;
           volunteer to participate in this study will sign the informed consent form (ICF) under&#xD;
           the premise of adequate understanding.&#xD;
&#xD;
        2. Collect clinical data of the participants and asses the severity of symptoms and the&#xD;
           risk of acute exacerbation of COPD patients. Clinical data include general condition,&#xD;
           history of past illness, history of present illness, personal history, family history&#xD;
           and the examination results of blood routine, pulmonary function and compatible computed&#xD;
           tomography. Breathlessness measurement adopt the modified British Medical Reseach&#xD;
           Council (mMRC); symptoms measurement adopt COPD assessment test (CAT); quality of life&#xD;
           measurement adopt St. George's Respiratory Questionnaire (SGRQ); risk of acute&#xD;
           exacerbation measurement adopt dyspnea，degree of airflow obstruction，smoking status and&#xD;
           the number of exacerbation (DOSE) scoring system.&#xD;
&#xD;
        3. Collect fecal specimens from the participants on the morning of the same day. During the&#xD;
           first three days of collection, they should keep their daily dietary habits and avoid&#xD;
           sudden changes in dietary habits. Considerations: first remove the urine, excrement into&#xD;
           a clean dry container, do not mix with urine and other sundries; the part of the feces&#xD;
           that do not contact the air and container is taken from the specimen; women who are&#xD;
           menstruating cannot be sampled. Each participant collect 3 fecal samples with a sterile&#xD;
           spoon in a sterile enzyme-free cryopreservation tube, label the sample name and date,&#xD;
           quickly placed in a -20℃ refrigerator, and transported to the hospital within 2 hours,&#xD;
           where they were stored at -80℃. Fecal microbiome are detected by 16S rRNA gene&#xD;
           sequencing and metabolite short chain fatty acid (SCFA) are detected by&#xD;
           Gaschromatography (GC).&#xD;
&#xD;
        4. Serum of participants are collected at the clinical laboratory and detect indicators&#xD;
           related to immune function by enzyme-linked immunosorbent assay (ELISA).&#xD;
&#xD;
        5. Explore the characteristics of intestinal microbiome during the early progression of&#xD;
           COPD, the correlation between the changes of intestinal microbiome and the severity and&#xD;
           risk of acute exacerbation of COPD, the correlation between microbial metabolites SCFA&#xD;
           and immune function of COPD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Breathlessness measurement</measure>
    <time_frame>1 month</time_frame>
    <description>modified British Medical Reseach Council (mMRC)：the score increases from 0 to 4，and higher scores mean a heavier symptom.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms measurement</measure>
    <time_frame>1 month</time_frame>
    <description>COPD assessment test (CAT)：the score increases from 0 to 40，and higher scores mean a heavier symptom.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life measurement</measure>
    <time_frame>1 month</time_frame>
    <description>St. George's Respiratory Questionnaire (SGRQ): the score increases from 0 to 100，and higher scores mean a heavier symptom.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of acute exacerbation of participants</measure>
    <time_frame>1 month</time_frame>
    <description>dyspnea，degree of airflow obstruction，smoking status，the number of exacerbation (DOSE): the score increases from 0 to 9，and higher scores mean a higher risk of acute exacerbation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>1 month</time_frame>
    <description>Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC), FEV1%predicted, MMEF25-75%: range from 0%-100%, and higher percentages mean a heavier symptom.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compatible computed tomography</measure>
    <time_frame>1 month</time_frame>
    <description>mean lung density</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of intestinal microbiome</measure>
    <time_frame>1 month</time_frame>
    <description>Alpha diversity，Beta diversity，Species differences between groups at different taxonomic levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contents of short chain fatty acid in fecal samples</measure>
    <time_frame>1 month</time_frame>
    <description>acetic acid, propionic acid, butyric acid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood routine</measure>
    <time_frame>1 month</time_frame>
    <description>neutrophilic granulocyte percent, eosinophilic granulocyte percent: higher percentages mean a heavier symptom.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of protein in serum</measure>
    <time_frame>1 month</time_frame>
    <description>fibrinogen, C-reactive protein, surfactant protein-D(SP-D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of enzyme in serum</measure>
    <time_frame>1 month</time_frame>
    <description>neutrophil elastase, alpha1-antitrypsin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of inflammatory factor in serum</measure>
    <time_frame>1 month</time_frame>
    <description>TNF-α, IFN-γ, IL-6, IL-8, IL-17</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of chemokine in serum</measure>
    <time_frame>1 month</time_frame>
    <description>CCL-16, CCL-18</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>HC，healthy control</arm_group_label>
    <description>18-65 years old，no smoking history，normal pulmonary function，normal compatible computed tomography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HG，high-risk COPD group</arm_group_label>
    <description>18-60 years old，≥10 pack-years smoking history，normal pulmonary function，normal compatible computed tomography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EG，early COPD group</arm_group_label>
    <description>18-60 years old，≥10 pack-years smoking history，and with any of the following abnormalities：&#xD;
Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) less than 80%;&#xD;
Compatible computed tomography abnormalities：airway abnormality and/or emphysema，air trapping, or bronchial thickening；&#xD;
FEV1 decline (≥60 mL per year).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG，mild and moderate COPD group</arm_group_label>
    <description>18-65 years old，FEV1/FVC&lt;70%，FEV1%predicted ≥50%.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal Specimen,Serum Specimen&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants are from Physical Examination Department and Respiratory and Critical Care&#xD;
        Medicine Department of the Second Affiliated Hospital of Xi 'an Jiaotong University.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥10 pack-years smoking history;&#xD;
&#xD;
          2. Examination of pulmonary function and compatible computed tomography meeting group&#xD;
             requirements (as shown in Groups and Interventions).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Take antibiotics, probiotics, prebiotics, synbiotics and other drugs that obviously&#xD;
             interfere with intestinal microbiome within 2 months;&#xD;
&#xD;
          2. Suffer from other chronic respiratory diseases other than COPD (such as bronchial&#xD;
             asthma, allergic rhinitis, pulmonary interstitial fibrosis, bronchiectasis, lung&#xD;
             cancer, etc.);&#xD;
&#xD;
          3. Suffer from severe intestinal diseases (such as inflammatory bowel disease, intestinal&#xD;
             infections, colorectal cancer, etc.);&#xD;
&#xD;
          4. Suffer from serious hematopoietic system diseases, and the brain, heart, liver, kidney&#xD;
             and other important organs are damaged;&#xD;
&#xD;
          5. Suffer from severe hypertension, coronary heart disease, diabetes and other chronic&#xD;
             diseases and taking drugs for long-term maintenance;&#xD;
&#xD;
          6. Suffer from active infectious diseases (hepatitis B, tuberculosis, etc.);&#xD;
&#xD;
          7. Pregnant or lactating women;&#xD;
&#xD;
          8. Patients with obvious anxiety, depression and other psychiatric symptoms and patients&#xD;
             with schizophrenia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Second Affiliated Hospital of Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yun Liu, MD</last_name>
    <phone>0086-13572887605</phone>
    <email>27556828@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yangfan Hou</last_name>
    <phone>0086-18534899825</phone>
    <email>1016429390@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yun Liu, MD</last_name>
      <phone>0086-13572887605</phone>
      <email>27556828@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Yangfan Hou</last_name>
      <phone>0086-18534899825</phone>
      <email>1016429390@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yun Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjEwNDE1EhFsaW5janl6ejIwMjAwMTAzNhoIbzR0Y24zenE%3D</url>
    <description>Correlation index analysis of intestinal flora and inflammatory factors in patients with chronic obstructive pulmonary disease</description>
  </link>
  <link>
    <url>https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjEwNDE1EhFsaW5janl6ejIwMjAwMTAzNhoIajdrcWM1dXA%3D</url>
    <description>Characteristics of intestinal flora in patients with chronic obstructive pulmonary disease and their correlation with inflammatory markers and pulmonary function status</description>
  </link>
  <reference>
    <citation>Tsay JJ, Segal LN. Could the Sputum Microbiota Be a Biomarker That Predicts Mortality after Acute Exacerbations of Chronic Obstructive Pulmonary Disease? Am J Respir Crit Care Med. 2019 May 15;199(10):1175-1176. doi: 10.1164/rccm.201811-2138ED.</citation>
    <PMID>30485116</PMID>
  </reference>
  <reference>
    <citation>Stockley RA, Halpin DMG, Celli BR, Singh D. Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. Am J Respir Crit Care Med. 2019 May 15;199(10):1195-1204. doi: 10.1164/rccm.201810-1860SO. Review.</citation>
    <PMID>30592902</PMID>
  </reference>
  <reference>
    <citation>Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P, Hansbro PM. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017 Jan;15(1):55-63. doi: 10.1038/nrmicro.2016.142. Epub 2016 Oct 3. Review.</citation>
    <PMID>27694885</PMID>
  </reference>
  <results_reference>
    <citation>GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep;5(9):691-706. doi: 10.1016/S2213-2600(17)30293-X. Epub 2017 Aug 16. Erratum in: Lancet Respir Med. 2017 Oct;5(10 ):e30.</citation>
    <PMID>28822787</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Chen CS, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Cao B, Dai H, Liang L, He J; China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9. Epub 2018 Apr 9.</citation>
    <PMID>29650248</PMID>
  </results_reference>
  <results_reference>
    <citation>Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2020 Mar 15;201(6):671-680. doi: 10.1164/rccm.201908-1644OC.</citation>
    <PMID>31770495</PMID>
  </results_reference>
  <results_reference>
    <citation>Bowerman KL, Rehman SF, Vaughan A, Lachner N, Budden KF, Kim RY, Wood DLA, Gellatly SL, Shukla SD, Wood LG, Yang IA, Wark PA, Hugenholtz P, Hansbro PM. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun. 2020 Nov 18;11(1):5886. doi: 10.1038/s41467-020-19701-0.</citation>
    <PMID>33208745</PMID>
  </results_reference>
  <results_reference>
    <citation>Jang YO, Lee SH, Choi JJ, Kim DH, Choi JM, Kang MJ, Oh YM, Park YJ, Shin Y, Lee SW. Fecal microbial transplantation and a high fiber diet attenuates emphysema development by suppressing inflammation and apoptosis. Exp Mol Med. 2020 Jul;52(7):1128-1139. doi: 10.1038/s12276-020-0469-y. Epub 2020 Jul 17.</citation>
    <PMID>32681029</PMID>
  </results_reference>
  <results_reference>
    <citation>Sprooten RTM, Lenaerts K, Braeken DCW, Grimbergen I, Rutten EP, Wouters EFM, Rohde GGU. Increased Small Intestinal Permeability during Severe Acute Exacerbations of COPD. Respiration. 2018;95(5):334-342. doi: 10.1159/000485935. Epub 2018 Jan 25.</citation>
    <PMID>29393240</PMID>
  </results_reference>
  <results_reference>
    <citation>Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012 Jan;5(1):7-18. doi: 10.1038/mi.2011.55. Epub 2011 Nov 16. Review.</citation>
    <PMID>22089028</PMID>
  </results_reference>
  <results_reference>
    <citation>Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol. 2019 Oct;20(10):1279-1290. doi: 10.1038/s41590-019-0451-9. Epub 2019 Sep 9. Review.</citation>
    <PMID>31501577</PMID>
  </results_reference>
  <results_reference>
    <citation>Mortaz E, Adcock IM, Ricciardolo FL, Varahram M, Jamaati H, Velayati AA, Folkerts G, Garssen J. Anti-Inflammatory Effects of Lactobacillus Rahmnosus and Bifidobacterium Breve on Cigarette Smoke Activated Human Macrophages. PLoS One. 2015 Aug 28;10(8):e0136455. doi: 10.1371/journal.pone.0136455. eCollection 2015.</citation>
    <PMID>26317628</PMID>
  </results_reference>
  <results_reference>
    <citation>Reale M, Boscolo P, Bellante V, Tarantelli C, Di Nicola M, Forcella L, Li Q, Morimoto K, Muraro R. Daily intake of Lactobacillus casei Shirota increases natural killer cell activity in smokers. Br J Nutr. 2012 Jul;108(2):308-14. doi: 10.1017/S0007114511005630. Epub 2011 Dec 6.</citation>
    <PMID>22142891</PMID>
  </results_reference>
  <results_reference>
    <citation>Tomoda K, Kubo K, Dairiki K, Yamaji T, Yamamoto Y, Nishii Y, Nakamura A, Yoshikawa M, Hamada K, Kimura H. Whey peptide-based enteral diet attenuated elastase-induced emphysema with increase in short chain fatty acids in mice. BMC Pulm Med. 2015 Jun 10;15:64. doi: 10.1186/s12890-015-0059-2.</citation>
    <PMID>26059026</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee SH, Yun Y, Kim SJ, Lee EJ, Chang Y, Ryu S, Shin H, Kim HL, Kim HN, Lee JH. Association between Cigarette Smoking Status and Composition of Gut Microbiota: Population-Based Cross-Sectional Study. J Clin Med. 2018 Sep 14;7(9). pii: E282. doi: 10.3390/jcm7090282.</citation>
    <PMID>30223529</PMID>
  </results_reference>
  <results_reference>
    <citation>Li N, Yang Z, Liao B, Pan T, Pu J, Hao B, Fu Z, Cao W, Zhou Y, He F, Li B, Ran P. Chronic exposure to ambient particulate matter induces gut microbial dysbiosis in a rat COPD model. Respir Res. 2020 Oct 19;21(1):271. doi: 10.1186/s12931-020-01529-3.</citation>
    <PMID>33076910</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Intestinal Microbiome</keyword>
  <keyword>Metabolite</keyword>
  <keyword>Immune Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan to share with others the deidentified individual-patient data (IPD) underlying the results presented in the article (including tables, figures, and appendices or supplementary material).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Immediately following publication; no end date</ipd_time_frame>
    <ipd_access_criteria>We plan to share with anyone who wishes to access the data for any purpose of analyses and data are available indefinitely.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

